Selected research
Market Outlook & Growth Opportunities
Global Diagnostic Imaging Agent Market Outlook and Growth Opportunities 2026
Market perspective
The global Diagnostic Imaging Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Diagnostic Imaging Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Diagnostic Imaging Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Diagnostic Imaging Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Diagnostic Imaging Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Diagnostic Imaging Agent market include GE HealthCare, Bracco Diagnostic, Guerbet, Abx Advanced Biochemical, Bayer AG, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company and Lantheus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Diagnostic Imaging Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Diagnostic Imaging Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Diagnostic Imaging Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diagnostic Imaging Agent market size, projected growth trends, production technologies, key applications, and end-use industries.
Diagnostic Imaging Agent Segment by Company
GE HealthCare
Bracco Diagnostic
Guerbet
Abx Advanced Biochemical
Bayer AG
Blue Earth Diagnostics
Cardinal Health
Eli Lilly and Company
Lantheus
Mallinckrodt
Navidea
Yantai Dongcheng
Foshan Rui Diao Pharmaceutical
Jubilant Pharma Limited
Diagnostic Imaging Agent Segment by Type
Conjugated Imaging Agent
Metabolic Imaging Agent
Blood Flow and Blood Volume Imaging Agents
Diagnostic Imaging Agent Segment by Application
Neurological Disease
Gastrointestinal Disease
Heart Disease
Tumor
Diagnostic Imaging Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Diagnostic Imaging Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Diagnostic Imaging Agent market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Diagnostic Imaging Agent significant trends, drivers, influence factors in global and regions.
6. To analyze Diagnostic Imaging Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Imaging Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Imaging Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Imaging Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Diagnostic Imaging Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Imaging Agent industry.
Chapter 3: Detailed analysis of Diagnostic Imaging Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Diagnostic Imaging Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Diagnostic Imaging Agent in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Conjugated Imaging Agent
- Metabolic Imaging Agent
- Blood Flow and Blood Volume Imaging Agents
Applications
- Neurological Disease
- Gastrointestinal Disease
- Heart Disease
- Tumor
Companies covered
- GE HealthCare
- Bracco Diagnostic
- Guerbet
- Abx Advanced Biochemical
- Bayer AG
- Blue Earth Diagnostics
- Cardinal Health
- Eli Lilly and Company
- Lantheus
- Mallinckrodt
- Navidea
- Yantai Dongcheng
- Foshan Rui Diao Pharmaceutical
- Jubilant Pharma Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Diagnostic Imaging Agent Sales Value (2021-2032)
- 1.2.2 Global Diagnostic Imaging Agent Sales Volume (2021-2032)
- 1.2.3 Global Diagnostic Imaging Agent Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Diagnostic Imaging Agent Market Dynamics
- 2.1 Diagnostic Imaging Agent Industry Trends
- 2.2 Diagnostic Imaging Agent Industry Drivers
- 2.3 Diagnostic Imaging Agent Industry Opportunities and Challenges
- 2.4 Diagnostic Imaging Agent Industry Restraints
3 Diagnostic Imaging Agent Market by Company
- 3.1 Global Diagnostic Imaging Agent Company Revenue Ranking in 2025
- 3.2 Global Diagnostic Imaging Agent Revenue by Company (2021-2026)
- 3.3 Global Diagnostic Imaging Agent Sales Volume by Company (2021-2026)
- 3.4 Global Diagnostic Imaging Agent Average Price by Company (2021-2026)
- 3.5 Global Diagnostic Imaging Agent Company Ranking (2024-2026)
- 3.6 Global Diagnostic Imaging Agent Company Manufacturing Base and Headquarters
- 3.7 Global Diagnostic Imaging Agent Company Product Type and Application
- 3.8 Global Diagnostic Imaging Agent Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Diagnostic Imaging Agent Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Diagnostic Imaging Agent Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Diagnostic Imaging Agent Market by Type
- 4.1 Diagnostic Imaging Agent Type Introduction
- 4.1.1 Conjugated Imaging Agent
- 4.1.2 Metabolic Imaging Agent
- 4.1.3 Blood Flow and Blood Volume Imaging Agents
- 4.2 Global Diagnostic Imaging Agent Sales Volume by Type
- 4.2.1 Global Diagnostic Imaging Agent Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Diagnostic Imaging Agent Sales Volume by Type (2021-2032)
- 4.2.3 Global Diagnostic Imaging Agent Sales Volume Share by Type (2021-2032)
- 4.3 Global Diagnostic Imaging Agent Sales Value by Type
- 4.3.1 Global Diagnostic Imaging Agent Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Diagnostic Imaging Agent Sales Value by Type (2021-2032)
- 4.3.3 Global Diagnostic Imaging Agent Sales Value Share by Type (2021-2032)
5 Diagnostic Imaging Agent Market by Application
- 5.1 Diagnostic Imaging Agent Application Introduction
- 5.1.1 Neurological Disease
- 5.1.2 Gastrointestinal Disease
- 5.1.3 Heart Disease
- 5.1.4 Tumor
- 5.2 Global Diagnostic Imaging Agent Sales Volume by Application
- 5.2.1 Global Diagnostic Imaging Agent Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Diagnostic Imaging Agent Sales Volume by Application (2021-2032)
- 5.2.3 Global Diagnostic Imaging Agent Sales Volume Share by Application (2021-2032)
- 5.3 Global Diagnostic Imaging Agent Sales Value by Application
- 5.3.1 Global Diagnostic Imaging Agent Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Diagnostic Imaging Agent Sales Value by Application (2021-2032)
- 5.3.3 Global Diagnostic Imaging Agent Sales Value Share by Application (2021-2032)
6 Diagnostic Imaging Agent Regional Sales and Value Analysis
- 6.1 Global Diagnostic Imaging Agent Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Diagnostic Imaging Agent Sales by Region (2021-2032)
- 6.2.1 Global Diagnostic Imaging Agent Sales by Region: 2021-2026
- 6.2.2 Global Diagnostic Imaging Agent Sales by Region (2027-2032)
- 6.3 Global Diagnostic Imaging Agent Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Diagnostic Imaging Agent Sales Value by Region (2021-2032)
- 6.4.1 Global Diagnostic Imaging Agent Sales Value by Region: 2021-2026
- 6.4.2 Global Diagnostic Imaging Agent Sales Value by Region (2027-2032)
- 6.5 Global Diagnostic Imaging Agent Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Diagnostic Imaging Agent Sales Value (2021-2032)
- 6.6.2 North America Diagnostic Imaging Agent Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Diagnostic Imaging Agent Sales Value (2021-2032)
- 6.7.2 Europe Diagnostic Imaging Agent Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Diagnostic Imaging Agent Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Diagnostic Imaging Agent Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Diagnostic Imaging Agent Sales Value (2021-2032)
- 6.9.2 South America Diagnostic Imaging Agent Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Diagnostic Imaging Agent Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Diagnostic Imaging Agent Sales Value Share by Country, 2025 VS 2032
7 Diagnostic Imaging Agent Country-level Sales and Value Analysis
- 7.1 Global Diagnostic Imaging Agent Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Diagnostic Imaging Agent Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Diagnostic Imaging Agent Sales by Country (2021-2032)
- 7.3.1 Global Diagnostic Imaging Agent Sales by Country (2021-2026)
- 7.3.2 Global Diagnostic Imaging Agent Sales by Country (2027-2032)
- 7.4 Global Diagnostic Imaging Agent Sales Value by Country (2021-2032)
- 7.4.1 Global Diagnostic Imaging Agent Sales Value by Country (2021-2026)
- 7.4.2 Global Diagnostic Imaging Agent Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.9.2 France Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.16.2 China Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.19.2 India Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Diagnostic Imaging Agent Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Diagnostic Imaging Agent Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Diagnostic Imaging Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 GE HealthCare
- 8.1.1 GE HealthCare Company Information
- 8.1.2 GE HealthCare Business Overview
- 8.1.3 GE HealthCare Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.1.4 GE HealthCare Diagnostic Imaging Agent Product Portfolio
- 8.1.5 GE HealthCare Recent Developments
- 8.2 Bracco Diagnostic
- 8.2.1 Bracco Diagnostic Company Information
- 8.2.2 Bracco Diagnostic Business Overview
- 8.2.3 Bracco Diagnostic Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Bracco Diagnostic Diagnostic Imaging Agent Product Portfolio
- 8.2.5 Bracco Diagnostic Recent Developments
- 8.3 Guerbet
- 8.3.1 Guerbet Company Information
- 8.3.2 Guerbet Business Overview
- 8.3.3 Guerbet Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Guerbet Diagnostic Imaging Agent Product Portfolio
- 8.3.5 Guerbet Recent Developments
- 8.4 Abx Advanced Biochemical
- 8.4.1 Abx Advanced Biochemical Company Information
- 8.4.2 Abx Advanced Biochemical Business Overview
- 8.4.3 Abx Advanced Biochemical Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Abx Advanced Biochemical Diagnostic Imaging Agent Product Portfolio
- 8.4.5 Abx Advanced Biochemical Recent Developments
- 8.5 Bayer AG
- 8.5.1 Bayer AG Company Information
- 8.5.2 Bayer AG Business Overview
- 8.5.3 Bayer AG Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Bayer AG Diagnostic Imaging Agent Product Portfolio
- 8.5.5 Bayer AG Recent Developments
- 8.6 Blue Earth Diagnostics
- 8.6.1 Blue Earth Diagnostics Company Information
- 8.6.2 Blue Earth Diagnostics Business Overview
- 8.6.3 Blue Earth Diagnostics Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Blue Earth Diagnostics Diagnostic Imaging Agent Product Portfolio
- 8.6.5 Blue Earth Diagnostics Recent Developments
- 8.7 Cardinal Health
- 8.7.1 Cardinal Health Company Information
- 8.7.2 Cardinal Health Business Overview
- 8.7.3 Cardinal Health Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Cardinal Health Diagnostic Imaging Agent Product Portfolio
- 8.7.5 Cardinal Health Recent Developments
- 8.8 Eli Lilly and Company
- 8.8.1 Eli Lilly and Company Company Information
- 8.8.2 Eli Lilly and Company Business Overview
- 8.8.3 Eli Lilly and Company Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Eli Lilly and Company Diagnostic Imaging Agent Product Portfolio
- 8.8.5 Eli Lilly and Company Recent Developments
- 8.9 Lantheus
- 8.9.1 Lantheus Company Information
- 8.9.2 Lantheus Business Overview
- 8.9.3 Lantheus Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Lantheus Diagnostic Imaging Agent Product Portfolio
- 8.9.5 Lantheus Recent Developments
- 8.10 Mallinckrodt
- 8.10.1 Mallinckrodt Company Information
- 8.10.2 Mallinckrodt Business Overview
- 8.10.3 Mallinckrodt Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Mallinckrodt Diagnostic Imaging Agent Product Portfolio
- 8.10.5 Mallinckrodt Recent Developments
- 8.11 Navidea
- 8.11.1 Navidea Company Information
- 8.11.2 Navidea Business Overview
- 8.11.3 Navidea Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Navidea Diagnostic Imaging Agent Product Portfolio
- 8.11.5 Navidea Recent Developments
- 8.12 Yantai Dongcheng
- 8.12.1 Yantai Dongcheng Company Information
- 8.12.2 Yantai Dongcheng Business Overview
- 8.12.3 Yantai Dongcheng Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Yantai Dongcheng Diagnostic Imaging Agent Product Portfolio
- 8.12.5 Yantai Dongcheng Recent Developments
- 8.13 Foshan Rui Diao Pharmaceutical
- 8.13.1 Foshan Rui Diao Pharmaceutical Company Information
- 8.13.2 Foshan Rui Diao Pharmaceutical Business Overview
- 8.13.3 Foshan Rui Diao Pharmaceutical Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Foshan Rui Diao Pharmaceutical Diagnostic Imaging Agent Product Portfolio
- 8.13.5 Foshan Rui Diao Pharmaceutical Recent Developments
- 8.14 Jubilant Pharma Limited
- 8.14.1 Jubilant Pharma Limited Company Information
- 8.14.2 Jubilant Pharma Limited Business Overview
- 8.14.3 Jubilant Pharma Limited Diagnostic Imaging Agent Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Jubilant Pharma Limited Diagnostic Imaging Agent Product Portfolio
- 8.14.5 Jubilant Pharma Limited Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Diagnostic Imaging Agent Value Chain Analysis
- 9.1.1 Diagnostic Imaging Agent Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Diagnostic Imaging Agent Sales Mode & Process
- 9.2 Diagnostic Imaging Agent Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Diagnostic Imaging Agent Distributors
- 9.2.3 Diagnostic Imaging Agent Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst